World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
52904
World Ranking
7820
National Ranking
4076

Research.com Recognitions

  • 2003 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Michael R. Grever is affiliated with The Ohio State University in the United States. Their research focuses primarily within the field of medicine, with significant contributions to genetics, pathology and forensic medicine, immunology, molecular biology, and oncology.

The scientist's work encompasses several key topics, including:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Acute Lymphoblastic Leukemia research
  • PI3K/AKT/mTOR signaling in cancer
  • Chronic Myeloid Leukemia Treatments
  • Advanced Breast Cancer Therapies

Frequent publication venues for Michael R. Grever include:

  • Blood
  • Leukemia
  • American Journal of Hematology
  • Journal of Clinical Oncology
  • Circulation

Notable recent papers authored or co-authored by Michael R. Grever are:

  • Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia, 2023, JACC CardioOncology
  • Ventricular arrhythmias and sudden death events following acalabrutinib initiation, 2022, Blood
  • Phase 2 study of ibrutinib in classic and variant hairy cell leukemia, 2021, Blood
  • The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib, 2021, Blood
  • Second cancer incidence in CLL patients receiving BTK inhibitors, 2020, Leukemia

Michael R. Grever has collaborated frequently with several researchers, including:

  • Kerry A. Rogers
  • Seema A. Bhat
  • Jennifer A. Woyach
  • Adam S. Kittai
  • James S. Blachly

Recognition in their professional field includes being named a Fellow of the American Association for the Advancement of Science (AAAS) in 2003 and membership in the Association of American Physicians.

Best Publications

  • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

    Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon

  • The National Cancer Institute: cancer drug discovery and development program.

    Michael R. Grever;Saul A. Schepartz;Bruce A. Chabner

  • Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

    B D Cheson;P A Cassileth;D R Head;C A Schiffer

  • Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

    Catherine P. Leith;Kenneth J. Kopecky;I-Ming Chen;Lisette Eijdems

  • Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

    Jeffrey G. Supko;Robert L. Hickman;Michael R. Grever;Louis Malspeis

  • Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

    Richard T. Kloos;Matthew D. Ringel;Michael V. Knopp;Nathan C. Hall

  • Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

    John C. Byrd;Timothy Murphy;Robin S. Howard;Margaret S. Lucas

  • Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    Kami J. Maddocks;Amy S. Ruppert;Gerard Lozanski;Nyla A. Heerema

  • Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Gerard Lozanski;Nyla A. Heerema;Ian W. Flinn;Lisa Smith

  • Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

    Steven D. Gore;Stephen Baylin;Elizabeth Sugar;Hetty E. Carraway

  • Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

    William Blum;Ramiro Garzon;Rebecca B. Klisovic;Sebastian Schwind

  • Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

    Ian W. Flinn;Donna S. Neuberg;Michael R. Grever;Gordon W. Dewald

  • A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

    James K. Weick;Kenneth J. Kopecky;Frederick R. Appelbaum;David R. Head

  • Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group

    Bruce D. Cheson;John M. Bennett;Kanti R. Rai;Michael R. Grever

  • RHODAMINE EFFLUX PATTERNS PREDICT P-GLYCOPROTEIN SUBSTRATES IN THE NATIONAL CANCER INSTITUTE DRUG SCREEN

    J S Lee;K Paull;M Alvarez;C Hose

  • A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

    John C. Byrd;Guido Marcucci;Mark R. Parthun;Jim J. Xiao

  • In vivo cultivation of tumor cells in hollow fibers.

    Melinda G. Hollingshead;Michael C. Alley;Richard F. Camalier;Betty J. Abbott

  • BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

    Jennifer A. Woyach;Amy S. Ruppert;Daphne Guinn;Amy Lehman

Frequent Co-Authors

John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Nyla A. Heerema
Nyla A. Heerema The Ohio State University
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Shujun Liu
Shujun Liu University of Minnesota
Steven M. Devine
Steven M. Devine The Ohio State University
A. Douglas Kinghorn
A. Douglas Kinghorn The Ohio State University
James T. Dalton
James T. Dalton St. Jude Children's Research Hospital
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
Kanti R. Rai
Kanti R. Rai Hofstra University
Donna Neuberg
Donna Neuberg Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related online degrees and career pathways to explore. Many health professionals are choosing flexible education options to boost their credentials while balancing work and life commitments.

For those aiming at healthcare leadership roles, affordable mha online programs can provide you with management skills and industry knowledge at a competitive cost. Nurses looking to advance clinical practice may consider the best online dnp programs, which focus on evidence-based care and leadership.

Pharmacy professionals can now pursue an online pharmacy degree, making it possible to enhance credentials remotely. Additionally, the growth in healthcare data and technology has made a him degree online a popular choice for those interested in health information management.

Each pathway offers unique opportunities and the convenience of online learning, allowing you to tailor your education to your career goals in the rapidly evolving healthcare landscape.

Best Scientists Citing Michael R. Grever

Trending Scientists